The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.

[1]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[2]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[3]  E. Ubogu,et al.  Interferon-&agr;-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient , 2008, European journal of gastroenterology & hepatology.

[4]  H. Elloumi,et al.  Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. , 2007, World journal of gastroenterology.

[5]  A. Piekarska,et al.  Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin , 2007, International journal of audiology.

[6]  P. Katsinelos,et al.  Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B , 2006 .

[7]  E. Yoshida,et al.  Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. , 2005, World journal of gastroenterology.

[8]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[9]  A. Tunca,et al.  Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. , 2004, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[10]  D. Denk,et al.  Sudden Hearing Loss in Patients with Chronic Hepatitis C Treated with Pegylated Interferon/Ribavirin , 2004, American Journal of Gastroenterology.

[11]  A. Öztürk,et al.  Effects of interferon-α2b on hearing , 2004 .

[12]  V. Tuohy,et al.  Interferon-γ production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss , 2002, Journal of Neuroimmunology.

[13]  E. Connick,et al.  Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Kakuda,et al.  Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? , 2000, Current opinion in infectious diseases.

[15]  R. Manna,et al.  Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis , 1998, The Journal of Laryngology & Otology.

[16]  T. Okanoue,et al.  Side effects of high-dose interferon therapy for chronic hepatitis C. , 1996, Journal of hepatology.

[17]  K. Shigeno,et al.  Interferon-induced sudden hearing loss. , 1995, Audiology : official organ of the International Society of Audiology.

[18]  K. Shigeno,et al.  Sudden hearing loss associated with interferon , 1994, The Lancet.